MedPath

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Phase 3
Completed
Conditions
Early Stage Parkinson's Disease
Interventions
Registration Number
NCT00335374
Lead Sponsor
Solvay Pharmaceuticals
Brief Summary

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
202
Inclusion Criteria
  • Patients who have completed S308.3.003 trial
Read More
Exclusion Criteria
  • Patients with medically relevant abnormal findings (ECG, physical examination, AEs) at end of the maintenance phase (visit M6, week 24) of study S308.3.003
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Pardoprunox-
Primary Outcome Measures
NameTimeMethod
Safety: laboratory data, adverse events, vital signs, ECG24 weeks
Secondary Outcome Measures
NameTimeMethod
UPDRS parts 1, 2 and 3, CGI-severity, CGI-Improvement, PDQ-39 total score: all change from baseline24 weeks

Trial Locations

Locations (75)

389

🇨🇳

Kaohsiung Hsien, Taiwan

387

🇨🇳

Kaohsiung, Taiwan

368

🇵🇱

Leszno, Poland

366

🇵🇱

Lublin, Poland

376

🇵🇹

Coimbra, Portugal

375

🇵🇹

Lisboa, Portugal

386

🇨🇳

Kwei-Shan, Taiwan

391

🇹🇭

Bangkok, Thailand

393

🇹🇭

Bangkok, Thailand

315

🇨🇿

Kralove, Czech Republic

313

🇨🇿

Olomouc, Czech Republic

310

🇨🇿

Ostrava, Czech Republic

312

🇨🇿

Pardubice, Czech Republic

311

🇨🇿

Plzen, Czech Republic

320

🇪🇪

Tallinn, Estonia

321

🇪🇪

Tartu, Estonia

332

🇩🇪

Bochum, Germany

331

🇩🇪

Gottingen, Germany

329

🇩🇪

Heidelberg, Germany

330

🇩🇪

Leipzig, Germany

328

🇩🇪

Lubeck, Germany

340

🇮🇳

Mumbai, India

348

🇮🇹

Grosseto, Italy

346

🇮🇹

Lido di Camaiore, Italy

362

🇳🇱

Groningen, Netherlands

428

🇱🇹

Kaunas, Lithuania

345

🇮🇹

Roma, Italy

427

🇱🇹

Vilnius, Lithuania

343

🇮🇹

Roma, Italy

429

🇱🇹

Vilnius, Lithuania

355

🇲🇾

Kelantan, Malaysia

357

🇲🇾

Kuala Lumpur, Malaysia

356

🇲🇾

Pulau Pinang, Malaysia

364

🇳🇱

Eindhoven, Netherlands

360

🇳🇱

Groningen, Netherlands

361

🇳🇱

Hertogenbosch, Netherlands

373

🇵🇱

Gdansk, Poland

371

🇵🇱

Kalisz, Poland

369

🇵🇱

Katowice, Poland

405

🇺🇸

Boston, Massachusetts, United States

408

🇺🇸

Oxnard, California, United States

421

🇺🇸

Augusta, Georgia, United States

413

🇺🇸

Oceanside, California, United States

419

🇺🇸

Birmingham, Alabama, United States

412

🇺🇸

Raleigh, North Carolina, United States

411

🇺🇸

Sarasota, Florida, United States

410

🇺🇸

Ft Wayne, Indiana, United States

417

🇺🇸

Lexington, Kentucky, United States

406

🇺🇸

Minneapolis, Minnesota, United States

381

🇿🇦

Pretoria, South Africa

344

🇮🇹

Pescara, Italy

379

🇿🇦

Sandton, South Africa

378

🇿🇦

Cape Town, South Africa

380

🇿🇦

Gauteng, South Africa

304

🇦🇺

Cheltenham, Australia

Site 300

🇦🇺

East Gosford, Australia

403

🇺🇸

Boca Raton, Florida, United States

420

🇺🇸

Boston, Massachusetts, United States

303

🇦🇺

Bedford Park, Australia

Site 402

🇺🇸

Dayton, Ohio, United States

301

🇦🇺

Concord, Australia

302

🇦🇺

Westmead, Australia

314

🇨🇿

Ostrava, Czech Republic

365

🇵🇱

Krakow, Poland

377

🇿🇦

Cape Town, South Africa

385

🇨🇳

Taipei, Taiwan

370

🇵🇱

Mosina, Poland

336

🇮🇳

Mumbai, India

326

🇩🇪

Wiesbaden, Germany

338

🇮🇳

Bangalore, India

339

🇮🇳

Hyderabaad, India

337

🇮🇳

Kerala, India

422

🇺🇸

New Haven, Connecticut, United States

388

🇨🇳

Hualien, Taiwan

394

🇹🇭

Ubonratchathani, Thailand

© Copyright 2025. All Rights Reserved by MedPath